Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Operations (2016 - 2025)

Vistagen Therapeutics' Cash from Operations history spans 14 years, with the latest figure at 17636000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 71.56% year-over-year to 17636000.0; the TTM value through Dec 2025 reached 60301000.0, down 54.54%, while the annual FY2025 figure was 42100000.0, 63.1% down from the prior year.
  • Cash from Operations for Q4 2025 was 17636000.0 at Vistagen Therapeutics, down from 13800000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4747000.0 in Q4 2023 and bottomed at 18800000.0 in Q2 2025.
  • The 4-year median for Cash from Operations is 10280000.0 (2024), against an average of 10848946.15.
  • The largest annual shift saw Cash from Operations tumbled 877.4% in 2021 before it dropped 26.77% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 17622500.0 in 2021, then soared by 73.06% to 4747000.0 in 2023, then tumbled by 116.56% to 10280000.0 in 2024, then tumbled by 71.56% to 17636000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Cash from Operations are 17636000.0 (Q4 2025), 13800000.0 (Q3 2025), and 18800000.0 (Q2 2025).